Achieve Life Sciences, Inc. ACHV 深 沪
已收盘 01-09 16:00:00 美东时间
5.56
+0.090
+1.65%
华盛通- 最 高5.62
- 今 开5.51
- 成交量 87.39万股
- 最 低 5.37
- 昨 收 5.47
- 总市值 2.84亿
- 52周最高 5.78
- 市盈率 静 --
- 换手率 1.71%
- 52周最低 1.84
- 委 比 -41.63%
- 总股本 5110.50万
- 历史最高 970.00
- 量 比 1.15
- 振 幅 4.57%
- 历史最低 1.84
- 每 手 1
- 风险率 0.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Watching Achieve Life Sciences; Shares Trading Higher, Hunterbrook Media Issues Report On Co, States Hunterbrook Capital Is Long
https://hntrbrk.com/achieve/
2025-12-31 00:17
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
Achieve Life Sciences, Inc. granted stock options to its Chief Legal Officer, Erik Atkisson, and two other new employees as an inducement to employment. Mr. Atkisson received options to purchase up to 250,000 shares, while the other employees collectively received options for 45,000 shares. The options vest over four years, with the first quarter vesting on the first anniversary of employment and the remaining shares vesting monthly thereafter. A...
2025-12-08 21:10
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
2025-11-26 10:07
Citizens Initiates Coverage On Achieve Life Sciences with Market Outperform Rating, Announces Price Target of $19
Citizens analyst Jason N. Butler initiates coverage on Achieve Life Sciences (NASDAQ:ACHV) with a Market Outperform rating and announces Price Target of $19.
2025-11-25 21:41
Achieve Life Sciences: Key Insights from Earnings Call
Achieve Life Sciences (($ACHV)) has held its Q3 earnings call. Read on for the ...
2025-11-07 08:56
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
Achieve Life Sciences Announces Key NDA Milestones For Cytisinicline; Co Submits 120-Day Update To FDA; Concludes ORCA-OL Safety Trial; DSMC Finds No Safety Concerns For Cytisinicline
Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced
2025-11-03 21:41
Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer
Achieve Life Sciences appoints Erik Atkisson as Chief Legal Officer. With over 25 years of experience in the biopharmaceutical industry, Atkisson will oversee legal strategy, corporate governance, compliance, and risk management. The company is advancing cytisinicline, a treatment for nicotine dependence, through regulatory review with an expected PDUFA date of June 20, 2026. Cytisinicline has shown promise in Phase 3 studies for smoking cessatio...
2025-10-20 12:30
Achieve, Disc, Revolution among winners of initial FDA national priority vouchers
Achieve Life Sciences (NASDAQ:ACHV), Disc Medicine (NASDAQ:IRON), and Revolution Medicines (NASDAQ:RVMD) have been selected among the first nine recipients of the FDA Commissioner’s National Priority ...
2025-10-17 19:12
Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket
Shares of CSX Corp (NASDAQ:CSX) rose sharply in pre-market trading after the co...
2025-10-17 17:55
